Fibronostics

Fibronostics Fibronostics is a global diagnostics company, shaping the future of noninvasive diagnostics with artificial intelligence.

We run an in-vitro diagnostics platform that focuses on screening, progression and prognosis of metabolic diseases. Fibronostics'​ LIVERFASt provides early detection and monitoring for patients with NAFLD & NASH. Where the current standard for diagnosis is risky and costly with mounting evidence calling for an efficacious and cost-effective non-invasive diagnostic tool, the LIVERFASt products are easy to use with economical advantages, and have proven clinical value.

See You at ADA 2026!ADA 2026 is almost here, and Fibronostics is looking forward to sharing new clinical evidence on the...
06/03/2026

See You at ADA 2026!

ADA 2026 is almost here, and Fibronostics is looking forward to sharing new clinical evidence on the role of noninvasive liver assessment in patients with MASLD, including those with type 2 diabetes (T2D).

Visit us at Booth 2306 at the Ernest N. Morial Convention Center, New Orleans, and join us for our poster presentations:

Poster 1780-P
LIVERFASt™ Outperforms FIB-4 in Sequential Combination with Vibration-Controlled Transient Elastography (VCTE) for Identifying ≥F3 Stage in Patients with MASLD Including Patients with Type 2 Diabetes
🗓 Sunday, June 7, 2026 🕧 12:30 PM – 1:30 PM

Poster 2607-P
Dynamics of Noninvasive Tests, LIVERFASt™, FIB-4 and VCTE (FibroScan) During Monitoring Therapy with THR-β Agonist Resmetirom in Patients with MASH: Update
🗓 Monday, June 8, 2026. 🕧 12:30 PM – 1:30 PM

These presentations highlight Fibronostics' ongoing commitment to advancing evidence-based, noninvasive liver assessment and supporting clearer clinical pathways for patients with metabolic liver disease.

Representing Fibronostics at ADA 2026 will be Brock Smith, Chief Executive Officer, David Cashio, Director of Business Operations, and Savannah Thomas, Director of Customer Operations. The team will be available throughout the meeting to discuss the latest clinical evidence and how LIVERFASt™ supports clearer assessment pathways in patients with MASLD and MASH.

We look forward to connecting with clinicians, researchers, collaborators, and partners throughout the meeting and discussing how innovative blood-based assessment tools can support more informed clinical decision-making.

Many patients with advanced fibrosis remain undetected despite having well-recognized metabolic risk factors.One of the ...
06/02/2026

Many patients with advanced fibrosis remain undetected despite having well-recognized metabolic risk factors.

One of the challenges with commonly used assessment tools such as FIB-4 is that they may miss a proportion of at-risk patients, particularly at earlier fibrosis stages when intervention opportunities are greatest.

Published studies have demonstrated that LIVERFASt™ delivers higher sensitivity and higher negative predictive value (NPV) than FIB-4, helping identify more patients who may require further assessment or follow-up.

Earlier identification can lead to earlier intervention, more informed clinical decisions, and potentially better patient outcomes.

Because the patients you don't identify are the patients you can't help.

Type 2 diabetes remains one of the strongest risk factors for advanced liver fibrosis in patients with MASLD. Yet identi...
06/01/2026

Type 2 diabetes remains one of the strongest risk factors for advanced liver fibrosis in patients with MASLD.
Yet identifying patients at highest risk continues to be a clinical challenge.

Recent analyses presented by Fibronostics demonstrate that LIVERFASt™ maintains strong diagnostic performance in patients with T2D, where traditional non-invasive assessment tools may show reduced sensitivity.

In patients with T2D:
• 68.6% sensitivity for identifying advanced fibrosis (≥F3) vs 36.2% for FIB-4
• 74.1% sensitivity for cirrhosis (F4) vs 44.4% for FIB-4
• Consistent diagnostic accuracy with AUROC 0.842 for ≥F3 and 0.854 for F4

These findings highlight the importance of using assessment tools that maintain performance in high-risk metabolic populations, supporting earlier identification, clearer risk stratification, and more informed clinical decision-making.

We look forward to sharing additional clinical data at ADA 2026.

Accurate fibrosis assessment is critical in MASLD — especially for patients with type 2 diabetes, where advanced fibrosi...
05/29/2026

Accurate fibrosis assessment is critical in MASLD — especially for patients with type 2 diabetes, where advanced fibrosis may remain under-identified.

At ADA 2026, Fibronostics will present clinical evidence showing that LIVERFASt™ outperformed FIB-4 for identifying ≥F3 fibrosis in patients with MASLD, including those with T2D.

In the overall MASLD population, LIVERFASt™ showed 66% sensitivity vs 36% for FIB-4 at the high-risk cut-off, with 72% PPV and 74% NPV. In patients with T2D, LIVERFASt™ showed 67% sensitivity vs 30% for FIB-4, supporting stronger identification in a high-risk population.

When used before VCTE in a sequential pathway, LIVERFASt™ also reduced unnecessary VCTE referrals and generated 20% more correctly classified patients compared with the recommended FIB-4 pathway.

More insights coming to ADA 2026.

We’re live at Pri-Med Nashville 2026 today and tomorrow!Fibronostics is pleased to be on-site at the Music City Center, ...
05/28/2026

We’re live at Pri-Med Nashville 2026 today and tomorrow!

Fibronostics is pleased to be on-site at the Music City Center, connecting with clinicians and healthcare professionals to discuss how LIVERFASt™ supports non-invasive liver assessment and clearer risk stratification in MASLD/MASH.

Visit us at the Davidson Ballroom Foyer:
Thursday, May 28: 6:30 AM – 2:45 PM
Friday, May 29: 6:30 AM – 1:30 PM

Fibronostics's CEO, Brock Smith, will be at the booth — stop by and say hello.

Treatment is only half the story. Monitoring is the other half. At EASL 2026, we presented data that takes the MASH moni...
05/28/2026

Treatment is only half the story. Monitoring is the other half.

At EASL 2026, we presented data that takes the MASH monitoring conversation a step further.

Our poster revealed the dynamics of LIVERFASt™, FIB-4, and VCTE (FibroScan) during Resmetirom therapy in patients with MASH — offering a real-world look at how these noninvasive tests evolve as treatment progresses.

As Resmetirom reshapes the MASH treatment landscape, knowing how NITs behave under therapy isn't just academic. It directly shapes how clinicians interpret response, adjust decisions, and ultimately serve their patients better.

Missed us in Barcelona? The conversation doesn't stop here.

Next stop: ADA 2026, New Orleans — June 5–8.

We're live at EASL 2026 in Barcelona — and the data is here. Today, Fibronostics is presenting two posters that advance ...
05/27/2026

We're live at EASL 2026 in Barcelona — and the data is here.

Today, Fibronostics is presenting two posters that advance the science of noninvasive liver assessment in MASLD and MASH:
Poster 1 — Outperforming the standard
LIVERFASt™ outperforms FIB-4 in sequential combination with VCTE for identifying advanced fibrosis (≥F3) in patients with MASLD — including those with type 2 diabetes (T2D). Where traditional tools fall short, LIVERFASt™ delivers greater clarity for the patients who need it most.
Poster 2 — Tracking treatment response
How do NITs evolve during therapy? We're presenting updated data on the dynamics of LIVERFASt™, FIB-4, and VCTE (FibroScan) during monitoring of Resmetirom — the THR-β agonist — in patients with MASH. Real-world monitoring data that matters for clinical decision-making.

The evidence is growing. The case for better, more precise noninvasive assessment has never been stronger.
Find us at the poster hall and let's talk liver science.

Next stop: ADA 2026, New Orleans, June 5–8.

In patients with MASLD — particularly those with type 2 diabetes (T2D) — advanced fibrosis may remain under-identified u...
05/26/2026

In patients with MASLD — particularly those with type 2 diabetes (T2D) — advanced fibrosis may remain under-identified using traditional assessment approaches.

Studies presented by Fibronostics have demonstrated that LIVERFASt™ shows improved sensitivity compared to FIB-4 in identifying patients with advanced fibrosis.

Because identifying more at-risk patients earlier may support clearer follow-up and referral pathways.

More to be presented at ADA 2026.

EASL 2026 is just 2 days away — and the conversation around MASLD assessment is more important than ever.For patients wi...
05/25/2026

EASL 2026 is just 2 days away — and the conversation around MASLD assessment is more important than ever.

For patients with metabolic dysfunction-associated steatotic liver disease — especially those living with type 2 diabetes (T2D) — indeterminate results from traditional assessment tools can stall critical referral and follow-up decisions.
Clearer pathways are needed. And better data is coming.

Following EASL, Fibronostics will be taking LIVERFASt™ to the ADA 2026 Scientific Sessions, presenting data on identifying advanced fibrosis in MASLD patients — including those with T2D.

Stay tuned. More to come.

Traditional assessment tools may leave uncertainty in patients with MASLD — particularly in populations with type 2 diab...
05/22/2026

Traditional assessment tools may leave uncertainty in patients with MASLD — particularly in populations with type 2 diabetes (T2D).

Indeterminate results can create challenges in referral and follow-up decisions, reinforcing the need for clearer assessment pathways.

At the upcoming ADA 2026 Scientific Sessions, Fibronostics will be presenting LIVERFASt™ data focused on identifying advanced fibrosis in patients with MASLD, including those with T2D.

More to come at ADA 2026.

Address

274 E. Eau Gallie Boulevard , #346 Indian Harbour Beach
Orlando, FL
32937

Telephone

+18885521603

Website

Alerts

Be the first to know and let us send you an email when Fibronostics posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Fibronostics:

Shortcuts

Share

Category